1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7.
Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4.
Voice of Customer
5. Global Anti-Tuberculosis
Therapeutics Market Outlook
5.1.
Market Size & Forecast
5.1.1.
By Value
5.2.
Market Share & Forecast
5.2.1.
By Disease Type (Active TB, Latent TB, Others)
5.2.2.
By Diagnosis and Treatment (Diagnosis (Blood Tests,
Imaging Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second
Line of Drugs, others), others)
5.2.3.
By End User (Hospitals, Specialty Clinics, Homecare,
others)
5.2.4.
By Region
5.2.5.
By Company (2022)
5.3.
Market Map
6. Asia Pacific Anti-Tuberculosis
Therapeutics Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1.
By Disease Type
6.2.2.
By Diagnosis and Treatment
6.2.3.
By End User
6.2.4.
By Country
6.3.
Asia Pacific: Country Analysis
6.3.1.
China Anti-Tuberculosis Therapeutics Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By
Disease Type
6.3.1.2.2.
By
Diagnosis and Treatment
6.3.1.2.3.
By End
User
6.3.2.
India Anti-Tuberculosis Therapeutics Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Disease
Type
6.3.2.2.2.
By
Diagnosis and Treatment
6.3.2.2.3.
By End
User
6.3.3.
Australia Anti-Tuberculosis Therapeutics Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By
Disease Type
6.3.3.2.2.
By
Diagnosis and Treatment
6.3.3.2.3.
By End
User
6.3.4.
Japan Anti-Tuberculosis Therapeutics Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By
Disease Type
6.3.4.2.2.
By
Diagnosis and Treatment
6.3.4.2.3.
By End
User
6.3.5.
South Korea Anti-Tuberculosis Therapeutics Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By
Disease Type
6.3.5.2.2.
By
Diagnosis and Treatment
6.3.5.2.3.
By End
User
7. Europe Anti-Tuberculosis
Therapeutics Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1.
By
Disease Type
7.2.2.
By
Diagnosis and Treatment
7.2.3.
By End
User
7.2.4.
By Country
7.3.
Europe: Country Analysis
7.3.1.
France Anti-Tuberculosis Therapeutics Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By
Disease Type
7.3.1.2.2.
By
Diagnosis and Treatment
7.3.1.2.3.
By End
User
7.3.2.
Germany Anti-Tuberculosis Therapeutics Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By
Disease Type
7.3.2.2.2.
By
Diagnosis and Treatment
7.3.2.2.3.
By End
User
7.3.3.
Spain Anti-Tuberculosis Therapeutics Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By
Disease Type
7.3.3.2.2.
By Diagnosis
and Treatment
7.3.3.2.3.
By End
User
7.3.4.
Italy Anti-Tuberculosis Therapeutics Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By
Disease Type
7.3.4.2.2.
By
Diagnosis and Treatment
7.3.4.2.3.
By End
User
7.3.5.
United Kingdom Anti-Tuberculosis Therapeutics Market
Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By
Disease Type
7.3.5.2.2.
By
Diagnosis and Treatment
7.3.5.2.3.
By End
User
8. North America Anti-Tuberculosis
Therapeutics Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1.
By Disease
Type
8.2.2.
By
Diagnosis and Treatment
8.2.3.
By End
User
8.2.4.
By Country
8.3.
North America: Country Analysis
8.3.1.
United States Anti-Tuberculosis Therapeutics Market
Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By
Disease Type
8.3.1.2.2.
By
Diagnosis and Treatment
8.3.1.2.3.
By End
User
8.3.2.
Mexico Anti-Tuberculosis Therapeutics Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By
Disease Type
8.3.2.2.2.
By
Diagnosis and Treatment
8.3.2.2.3.
By End
User
8.3.3.
Canada Anti-Tuberculosis Therapeutics Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By
Disease Type
8.3.3.2.2.
By
Diagnosis and Treatment
8.3.3.2.3.
By End
User
9. South America Anti-Tuberculosis
Therapeutics Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1.
By
Disease Type
9.2.2.
By
Diagnosis and Treatment
9.2.3.
By End
User
9.2.4.
By Country
9.3.
South America: Country Analysis
9.3.1.
Brazil Anti-Tuberculosis Therapeutics Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By
Disease Type
9.3.1.2.2.
By
Diagnosis and Treatment
9.3.1.2.3.
By End
User
9.3.2.
Argentina Anti-Tuberculosis Therapeutics Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By
Disease Type
9.3.2.2.2.
By
Diagnosis and Treatment
9.3.2.2.3.
By End
User
9.3.3.
Colombia Anti-Tuberculosis Therapeutics Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By
Disease Type
9.3.3.2.2.
By
Diagnosis and Treatment
9.3.3.2.3.
By End
User
10. Middle East and Africa
Anti-Tuberculosis Therapeutics Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Diagnosis and Treatment
10.2.3. By End User
10.2.4. By Country
10.3.
MEA: Country Analysis
10.3.1. South Africa Anti-Tuberculosis
Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By
Disease Type
10.3.1.2.2.
By
Diagnosis and Treatment
10.3.1.2.3.
By End
User
10.3.2. Saudi Arabia Anti-Tuberculosis
Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By
Disease Type
10.3.2.2.2.
By
Diagnosis and Treatment
10.3.2.2.3.
By End
User
10.3.3. UAE Anti-Tuberculosis
Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Disease
Type
10.3.3.2.2.
By
Diagnosis and Treatment
10.3.3.2.3.
By End
User
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers & Acquisitions
13.
Global Anti-Tuberculosis Therapeutics Market: SWOT
Analysis
14. Porter’s Five Forces
Analysis
14.1.
Competition in the Industry
14.2.
Potential of New Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute Product
15.
PESTLE Analysis
16.
Competitive Landscape
16.1.
AstraZeneca Plc
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products &
Services
16.1.4. Financials (In case
of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2.
Johnson & Johnson Private Limited
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products &
Services
16.2.4. Financials (In case
of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3.
Eli Lilly and Company
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products &
Services
16.3.4. Financials (In case
of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4. F. Hoffmann-La Roche Ltd.
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products &
Services
16.4.4. Financials (In case
of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5. Mylan N.V.
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products &
Services
16.5.4. Financials (In case
of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6.
Teva Pharmaceutical Industries Ltd.
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products &
Services
16.6.4. Financials (In case
of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7.
Sanofi SA
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products &
Services
16.7.4. Financials (In case
of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8.
Novartis AG
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products &
Services
16.8.4. Financials (In case
of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9. Sun Pharmaceutical
Industries Ltd.
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products &
Services
16.9.4. Financials (In case
of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10. Merck & Co., Inc.
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products &
Services
16.10.4. Financials (In case
of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17. Strategic Recommendations
18. About Us & Disclaimer